Exploring the use of circulating tumor DNA for mutational signature analysis

Lung Cancer. 2024 Jul:193:107844. doi: 10.1016/j.lungcan.2024.107844. Epub 2024 May 31.

Authors

Sophie M Ernst¹, Ronald van Marion², Jan H von der Thüsen², Hendrikus J Dubbink², Anne-Marie C Dingemans³

Affiliations

¹ Department of Respiratory Medicine, University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
² Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
³ Department of Respiratory Medicine, University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Electronic address: a.dingemans@erasmusmc.nl.

PMID: 38833851
DOI: 10.1016/j.lungcan.2024.107844

No abstract available

Keywords: Biomarker; NSCLC; ctDNA.

Publication types

Letter

MeSH terms

Biomarkers, Tumor / genetics
Circulating Tumor DNA* / blood
Circulating Tumor DNA* / genetics
DNA Mutational Analysis
Humans
Lung Neoplasms / diagnosis
Lung Neoplasms / genetics
Mutation*

Substances

Circulating Tumor DNA
Biomarkers, Tumor